Characterizing AAVs

Application Note Heightened Characterization of AAVs by SEC-MALS with XBridge™ Premier GTx BEH™ SEC 450 Å 2.5 µm Columns Lavelay Kizekai, Balasubrahmanyam Addepalli, Matthew A. Lauber Waters Corporation For in vitro diagnostic use. Not available in all countries. Abstract Gene…

Separation Solutions to Accelerate Next Generation Gene Therapy Development The therapeutics you are working on are cutting edge, complex and ultimately life-changing. Waters is here to help partner with you from bench to clinic through these challenges. COMMON ANALYTICAL QUESTIONS…

Advanced Therapeutic Medicinal Products: Adeno-associated Virus (AAV) The Promise of Viral Vector Gene Therapy using AAV 7000 Monogenic Diseases 20 of 22 4 Years Children with spinal muscular atrophy (SMA) given the ability to thrive with Zolgensma® (AAV) at 91%…

Developing the analytics and analytical workflows supporting the analysis of the next generation of biotherapeutic and gene therapies. Scott J. Berger, Ph.D. and Ximo Zhang, Ph.D. Waters Lunch Seminar Tuesday January 28, 2020 WCBP 2020 Diamond Program Partner ©2020 Waters…